Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa

Int J Antimicrob Agents. 2017 Feb;49(2):266-268. doi: 10.1016/j.ijantimicag.2016.11.005. Epub 2016 Dec 2.

Authors

Marc Xipell¹, Marta Bodro², Francesc Marco³, Ricardo A Losno¹, Celia Cardozo¹, Alex Soriano⁴

Affiliations

¹ Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
² Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. Electronic address: mbodro@clinic.ub.es.
³ Microbiology Department, Hospital Clínic-ISGLOBAL, University of Barcelona, Barcelona, Spain.
⁴ Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain. Electronic address: asoriano@clinic.ub.es.

PMID: 27979500
DOI: 10.1016/j.ijantimicag.2016.11.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anti-Bacterial Agents / therapeutic use*
Azabicyclo Compounds / therapeutic use*
Ceftazidime / therapeutic use*
Colistin / therapeutic use
Drug Combinations
Drug Resistance, Multiple, Bacterial
Drug Therapy, Combination / methods
Female
Humans
Lung Abscess / diagnostic imaging
Lung Abscess / drug therapy
Lung Abscess / microbiology
Male
Meningitis / drug therapy
Meningitis / microbiology
Middle Aged
Pseudomonas Infections / diagnostic imaging
Pseudomonas Infections / drug therapy*
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Radiography, Thoracic
Tomography, X-Ray Computed
Treatment Outcome
beta-Lactamase Inhibitors / therapeutic use*

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Drug Combinations
avibactam, ceftazidime drug combination
beta-Lactamase Inhibitors
Ceftazidime
Colistin